NCT04949490View on ClinicalTrials.gov

A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

July 26, 2021

Primary Completion Date

April 14, 2022

Study Completion Date

September 16, 2022

Conditions
COVID-19SARS-CoV-2 Infection
Interventions
BIOLOGICAL

BNT162b2s01

intramuscular (IM) injection

BIOLOGICAL

BNT162b2

IM injection

Trial Locations (4)

13353

CRS Clinical Research Services Berlin GmbH, Berlin

60590

University Hospital Frankfurt, Infectiology, Frankfurt

68167

CRS Clinical Research Services Mannheim GmbH, Mannheim

69117

University Hospital Heidelberg, Clinical Pharmacology, Heidelberg

Sponsors

Lead Sponsor

BioNTech SE
All Listed Sponsors
lead

BioNTech SE

INDUSTRY